Search STTK
Shattuck Labs, Inc.
Nasdaq · CIK 1680367
Last close6.73
Daily change-0.11 (-1.61%)
10 Years gain-65.22%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STTK · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
47.8Momentum
0.0Acceleration
40.0Confidence
83.0Annual Revenue7
Quarterly Revenue21
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.7 / 25
Quality8.6 / 25
Capital Efficiency10.1 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 109.4018 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 4228.3343 percentage points.
Heavy share dilution · HIGHDiluted share count increased 154.6399%.
Key Metrics
Revenue Growth TTM-82.52%OK
Revenue CAGR 3Y15.32%OK
Gross Margin100%OK
Operating Margin-5,544.8%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-40.67%OK
Incremental Operating Margin 3Y1,172.45%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y154.64%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.00M | $1.00M | -$51.51M | -$39.88M | -$39.95M | 100% | -5,150.8% | -3,995.3% | -161.36% | 69.58M |
| 2025 FY Dec 31, 2024 | $5.72M | $5.72M | -$80.57M | -$60.52M | -$60.57M | 100% | -1,408.27% | -1,058.8% | -350.49% | 50.76M |
| 2024 FY Dec 31, 2023 | $1.66M | $1.66M | -$91.96M | -$81.23M | -$81.64M | 100% | -5,549.61% | -4,926.67% | -501.75% | 42.6M |
| 2023 FY Dec 31, 2022 | $652,000.00 | $652,000.00 | -$103.33M | -$94.50M | -$106.11M | 100% | -15,848.01% | -16,274.85% | -914.16% | 42.38M |
| 2022 FY Dec 31, 2021 | $30.02M | $30.02M | -$45.27M | -$57.12M | -$65.04M | 100% | -150.81% | -216.68% | n/a | 42.03M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.00M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-055483, 0001680367-25-000057 |
| Revenue Growth TTM | -82.52% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-055483, 0001680367-25-000057 |
| Revenue CAGR 3Y | 15.32% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-014989 |
| Revenue CAGR 5Y | -36.82% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-014989 |
| Gross Profit CAGR 3Y | 15.32% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-014989 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-055483, 0001680367-25-000057 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-055483, 0001680367-25-000057 |
| Operating Margin | -5,544.8% | Operating Income / Revenue | OK | 0001628280-26-055483, 0001680367-25-000057 |
| ROIC | -40.67% | NOPAT / Average Invested Capital | OK | 0001628280-26-055483, 0001680367-25-000057 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-055483 |
| Current Ratio | 27.59x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.01 | Revenue / Diluted Shares | OK | 0001628280-26-055483, 0001680367-25-000057 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |